JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Setting

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

A3660 Nilotinib monohydrochloride monohydrate

Summary: Bcr-Abl inhibitor

≥50 mg/mL
A8603 GNF 2

Summary: Bcr-Abl inhibitor

insoluble in H2O; ≥18.7 mg/mL
A8604 GNF 5

Target: Bcr-Abl

Summary: Bcr-Abl inhibitor
A8605 1-Naphthyl PP1

Summary: Src family kinases inhibitor

Soluble in DMSO
A8606 PD 180970

Summary: P210bcr/abl tyrosine kinase inhibitor

<21.46 mg/mL
A8607 PPY A

Target: Abl kinases

Summary: Abl kinases inhibitor

<37.24 mg/mL
A8812 PD173955

Target: Bcr-Abl|Src

Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,

≥22.15 mg/mL
B1402 GZD824

Target: Bcr-Abl

Summary: Bcr-Abl inhibitor,novel orally bioavailable

≥36.25 mg/mL
A3017 Dasatinib (BMS-354825)

4 Citation

Summary: Src and BCR-Abl inhibitor

≥24.4 mg/mL
B1011 Bafetinib (INNO-406)

2 Citation

Summary: Bcr-Abl/Lyn tyrosine kinase inhibitor

≥57.7 mg/mL